[go: up one dir, main page]

NL300926I2 - Afamelanotide - Google Patents

Afamelanotide Download PDF

Info

Publication number
NL300926I2
NL300926I2 NL300926C NL300926C NL300926I2 NL 300926 I2 NL300926 I2 NL 300926I2 NL 300926 C NL300926 C NL 300926C NL 300926 C NL300926 C NL 300926C NL 300926 I2 NL300926 I2 NL 300926I2
Authority
NL
Netherlands
Prior art keywords
subject
afamelanotide
photodermatoses
photosensitivity
exacerbated
Prior art date
Application number
NL300926C
Other languages
English (en)
Original Assignee
Clinuvel Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006904745A external-priority patent/AU2006904745A0/en
Application filed by Clinuvel Pharmaceuticals Ltd filed Critical Clinuvel Pharmaceuticals Ltd
Publication of NL300926I2 publication Critical patent/NL300926I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Birds (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NL300926C 2006-08-31 2018-01-31 Afamelanotide NL300926I2 (nl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2006904745A AU2006904745A0 (en) 2006-08-31 Method for Treatment of Photodermatoses
AU2007900862A AU2007900862A0 (en) 2007-02-21 Method for treatment of photodermatoses
EP07800234.2A EP2056855B1 (en) 2006-08-31 2007-08-31 Alpha-msh derivatives for the treatment of photodermatoses

Publications (1)

Publication Number Publication Date
NL300926I2 true NL300926I2 (nl) 2018-03-20

Family

ID=39135428

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300926C NL300926I2 (nl) 2006-08-31 2018-01-31 Afamelanotide

Country Status (17)

Country Link
US (1) US8334265B2 (nl)
EP (2) EP2056855B1 (nl)
AU (1) AU2007291886B2 (nl)
CA (1) CA2662163C (nl)
CY (1) CY1115804T1 (nl)
DK (2) DK2865422T3 (nl)
ES (2) ES2525476T3 (nl)
HK (1) HK1130208A1 (nl)
HU (2) HUE035074T2 (nl)
LU (1) LUC00062I2 (nl)
NL (1) NL300926I2 (nl)
NZ (1) NZ575133A (nl)
PL (2) PL2056855T3 (nl)
PT (2) PT2056855E (nl)
SI (2) SI2865422T1 (nl)
WO (1) WO2008025094A1 (nl)
ZA (1) ZA200901364B (nl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008025074A1 (en) * 2006-08-28 2008-03-06 Clinuvel Pharmaceuticals Limited Method for reducing incidence or rate of development of skin cancers and related conditions
WO2009103816A1 (en) * 2008-02-22 2009-08-27 Clinuvel Pharmaceuticals Limited Method for treatment of photosensitivity and phototoxicity
EP2957292B1 (en) * 2008-03-27 2017-12-13 Clinuvel Pharmaceuticals Limited Therapy for vitiligo
EA020959B1 (ru) 2009-06-08 2015-03-31 Палатин Текнолоджиз, Инк. Пептиды, специфичные к меланокортиновым рецепторам
WO2010144341A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
US8979797B2 (en) * 2010-12-16 2015-03-17 Ams Research Corporation High pressure delivery system and method for treating pelvic disorder using large molecule therapeutics
EP2487185A1 (en) * 2011-02-11 2012-08-15 Clinuvel Pharmaceuticals Limited Hexapeptide with improved activity in the repair of cellular DNA of dermal cells
US9371555B2 (en) 2012-06-01 2016-06-21 Concordia Laboratories Inc. Lighting systems and methods of using lighting systems for in vitro potency assay for photofrin
WO2014198890A1 (en) * 2013-06-13 2014-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of erythropoietic protoporphyria
WO2015063099A1 (en) * 2013-10-28 2015-05-07 Clinuvel Ag Alpha-msh analogues for use in the treatment of hailey-hailey disease
WO2015063102A1 (en) * 2013-10-28 2015-05-07 Clinuvel Ag Alpha-msh analogues for use in bullous disease
EP3088418A1 (en) 2015-04-28 2016-11-02 Vallaurix Pte. Ltd. Pharmaceutical compound
EP3088417A1 (en) 2015-04-28 2016-11-02 Vallaurix Pte. Ltd. Pharmaceutical compound
WO2018142318A1 (en) * 2017-02-01 2018-08-09 Clinuvel Pharmaceuticals Ltd Alpha-msh analogues used in the treatment of xeroderma pigmentosum
WO2021251450A1 (ja) 2020-06-10 2021-12-16 田辺三菱製薬株式会社 ポルフィリン症の予防又は治療剤
CA3186880A1 (en) 2020-06-10 2021-12-16 Mitsubishi Tanabe Pharma Corporation Prophylactic or therapeutic agent for porphyria
CN115768428A (zh) 2020-06-10 2023-03-07 田边三菱制药株式会社 光照性皮肤病的预防或治疗剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457864A (en) 1981-10-23 1984-07-03 University Patents, Inc. Synthetic analogues of α-melanotropin
US4485039A (en) 1982-06-11 1984-11-27 University Patents, Inc. Synthetic analogues of α-melanotropin
WO1987004623A1 (en) 1986-02-03 1987-08-13 University Patents, Inc. Method of stimulating melanocytes by topical application of analogs of alpha-msh, and compositions for use in same
US5674839A (en) 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
US5049547A (en) 1988-02-11 1991-09-17 University Patents, Inc. Composition for stimulating integumental melanocytes
US5252318A (en) 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
WO1998000166A1 (en) 1996-07-03 1998-01-08 Merial, Inc. Recombinant canine adenovirus (cav) containing exogenous dna
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
DE69934688T2 (de) 1998-05-15 2007-10-18 Quark Biotech, Inc., Pleasanton Durch mechanischen stress induzierte gene, deren expressionsprodukte und deren verwendung.
US20050142078A1 (en) * 2002-02-26 2005-06-30 Dorr Robert T. Method of stimulation of melanin production and induction of skin tanning
NZ582130A (en) * 2004-08-04 2011-11-25 Clinuvel Pharmaceuticals Ltd Methods of inducing melanogenesis in a subject
NZ554427A (en) * 2004-10-08 2010-09-30 Clinuvel Pharmaceuticals Ltd Compositions and methods for inducing melanogenesis in a subject utilising afamelanotide
WO2008025074A1 (en) * 2006-08-28 2008-03-06 Clinuvel Pharmaceuticals Limited Method for reducing incidence or rate of development of skin cancers and related conditions

Also Published As

Publication number Publication date
CA2662163C (en) 2015-11-24
DK2056855T3 (en) 2014-12-15
EP2056855A1 (en) 2009-05-13
EP2865422A1 (en) 2015-04-29
PT2865422T (pt) 2017-11-14
PT2056855E (pt) 2014-12-12
ES2525476T3 (es) 2014-12-23
AU2007291886B2 (en) 2013-01-10
NZ575133A (en) 2011-11-25
WO2008025094A1 (en) 2008-03-06
US20100120668A1 (en) 2010-05-13
CA2662163A1 (en) 2008-03-06
ZA200901364B (en) 2010-06-30
EP2056855A4 (en) 2013-06-19
SI2056855T1 (sl) 2015-01-30
PL2865422T3 (pl) 2018-01-31
LUC00062I1 (nl) 2018-02-08
ES2646049T3 (es) 2017-12-11
SI2865422T1 (sl) 2017-12-29
CY1115804T1 (el) 2017-01-25
LUC00062I2 (nl) 2018-03-28
EP2865422B1 (en) 2017-10-18
EP2056855B1 (en) 2014-09-17
HUS1800006I1 (hu) 2018-05-02
HK1130208A1 (en) 2009-12-24
US8334265B2 (en) 2012-12-18
DK2865422T3 (da) 2017-11-20
HUE035074T2 (en) 2018-05-02
AU2007291886A1 (en) 2008-03-06
PL2056855T3 (pl) 2015-04-30

Similar Documents

Publication Publication Date Title
NL300926I2 (nl) Afamelanotide
EA201070447A1 (ru) Способ обработки волос
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2008115469A3 (en) Role of hedgehog signaling in atherosclerosis and cardiovascular disease
WO2007087468A3 (en) Adiponectin for treatment of various disorders
WO2008070859A3 (en) Treatment of skin conditions by dickkopf1 (dkk1)
WO2009089494A3 (en) Pharmaceutical compositions
ATE416177T1 (de) Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer
MX2010006823A (es) Metodos para el tratamiento de la gota.
LT2894165T (lt) Būdai ir kompozicijos, skirti su komplementu susijusių sutrikimų gydymui
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
DK1761266T3 (da) Forbindelser, formuleringer og fremgangsmåder til at behandle eller forebygge inflammatoriske hudsygdomme
WO2010025321A3 (en) Method for treating multiple sclerosis patients with anti-il2r antibodies
ATE453642T1 (de) Substituierte phenylaminopyrimidine
WO2010062581A3 (en) A botanical composition for enhanced skin repair and uses thereof
WO2008104385A8 (en) Method for the treatment of amyloidoses
WO2009041663A1 (ja) 皮膚疾患の予防及び／または治療剤
WO2010011581A3 (en) Polysaccharides extract from dendrobium for treating allergic diseases
WO2010086828A3 (en) Agonist anti-trkb monoclonal antibodies
AU2010279892A8 (en) Humanized anti-amyloid-b oligomer antibody
UA102097C2 (ru) Способ лечения воспалительного заболевания с применением соединения, которое нейтрализует gm-csf, и соединения, которое нейтрализует il-17
NZ588213A (en) Alpha-msh analogues for treating or preventing vitiligo
WO2007079312A3 (en) Compositions and methods for treating actin-mediated medical conditions
FI20095600L (fi) Koostumus ihosairauksien hoitoa varten